These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 8891133)
41. Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine. Rastogi N; Goh KS; Bryskier A; Devallois A Antimicrob Agents Chemother; 1996 Nov; 40(11):2483-7. PubMed ID: 8913450 [TBL] [Abstract][Full Text] [Related]
42. Rapid direct detection of multiple rifampin and isoniazid resistance mutations in Mycobacterium tuberculosis in respiratory samples by real-time PCR. Marín M; García de Viedma D; Ruíz-Serrano MJ; Bouza E Antimicrob Agents Chemother; 2004 Nov; 48(11):4293-300. PubMed ID: 15504855 [TBL] [Abstract][Full Text] [Related]
43. Bactericidal action of pulsed exposure to rifampicin, ethambutol, isoniazid & pyrazinamide on Mycobacterium tuberculosis in vitro. Paramasivan CN; Herbert D; Prabhakar R Indian J Med Res; 1993 Jul; 97():145-50. PubMed ID: 8406638 [TBL] [Abstract][Full Text] [Related]
44. Validation of a rapid method for detection of M. tuberculosis resistance to INH and RMP in Lima, Peru. De Kantor IN Int J Tuberc Lung Dis; 2006 Jun; 10(6):707; author reply 707-8. PubMed ID: 16776461 [No Abstract] [Full Text] [Related]
45. Comparison of fixed concentration and fixed ratio options for dilution susceptibility testing of gram-negative bacilli to ampicillin and ampicillin/sulbactam. Pfaller MA; Barry AL; Fuchs PC; Gerlach EH; Hardy DJ; McLaughlin JC Eur J Clin Microbiol Infect Dis; 1993 May; 12(5):356-62. PubMed ID: 8354303 [TBL] [Abstract][Full Text] [Related]
46. The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH. Iacobino A; Giannoni F; Pardini M; Piccaro G; Fattorini L Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31010861 [TBL] [Abstract][Full Text] [Related]
47. In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis. Yamamoto T; Amitani R; Suzuki K; Tanaka E; Murayama T; Kuze F Antimicrob Agents Chemother; 1996 Feb; 40(2):426-8. PubMed ID: 8834891 [TBL] [Abstract][Full Text] [Related]
48. Role of individual drugs in the chemotherapy of tuberculosis. Mitchison DA Int J Tuberc Lung Dis; 2000 Sep; 4(9):796-806. PubMed ID: 10985648 [TBL] [Abstract][Full Text] [Related]
49. Bactericidal action of oral ampicillin/sulbactam against Mycobacterium leprae. Randhawa B; Harris EB; Prabhakaran K J Antimicrob Chemother; 1999 Aug; 44(2):279-81. PubMed ID: 10473236 [TBL] [Abstract][Full Text] [Related]
50. Clinical evaluation of the microscopic observation drug susceptibility assay for detection of Mycobacterium tuberculosis resistance to isoniazid or rifampin. Mello FC; Arias MS; Rosales S; Marsico AG; Pavón A; Alvarado-Gálvez C; Pessôa CL; Pérez M; Andrade MK; Kritski AL; Fonseca LS; Chaisson RE; Kimerling ME; Dorman SE J Clin Microbiol; 2007 Oct; 45(10):3387-9. PubMed ID: 17699652 [TBL] [Abstract][Full Text] [Related]
51. Mutant prevention concentration of isoniazid, rifampicin and rifabutin against Mycobacterium tuberculosis. Rodríguez JC; Cebrián L; Ruiz M; López M; Royo G Chemotherapy; 2005 May; 51(2-3):76-9. PubMed ID: 15870500 [TBL] [Abstract][Full Text] [Related]
52. Effect of drug resistance on the generation of secondary cases of tuberculosis. Burgos M; DeRiemer K; Small PM; Hopewell PC; Daley CL J Infect Dis; 2003 Dec; 188(12):1878-84. PubMed ID: 14673768 [TBL] [Abstract][Full Text] [Related]
53. Synergistic activities of antituberculous drugs with cerulenin and trans-cinnamic acid against Mycobacterium tuberculosis. Rastogi N; Goh KS; Horgen L; Barrow WW FEMS Immunol Med Microbiol; 1998 Jun; 21(2):149-57. PubMed ID: 9685005 [TBL] [Abstract][Full Text] [Related]
54. Increasing drug resistance of Mycobacterium tuberculosis isolates in Ontario, Canada, 1987-1998. Remis RS; Jamieson F; Chedore P; Haddad A; Vernich L Clin Infect Dis; 2000 Aug; 31(2):427-32. PubMed ID: 10987700 [TBL] [Abstract][Full Text] [Related]
55. Quantitative analysis of mRNA as a marker for viability of Mycobacterium tuberculosis. Hellyer TJ; DesJardin LE; Hehman GL; Cave MD; Eisenach KD J Clin Microbiol; 1999 Feb; 37(2):290-5. PubMed ID: 9889206 [TBL] [Abstract][Full Text] [Related]
56. Comparison of line probe assay to BACTEC MGIT 960 system for susceptibility testing of first and second-line anti-tuberculosis drugs in a referral laboratory in South Africa. Maningi NE; Malinga LA; Antiabong JF; Lekalakala RM; Mbelle NM BMC Infect Dis; 2017 Dec; 17(1):795. PubMed ID: 29282012 [TBL] [Abstract][Full Text] [Related]
57. Ampicillin, sulbactam, and rifampin combination treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis in rabbits. Chambers HF; Kartalija M; Sande M J Infect Dis; 1995 Apr; 171(4):897-902. PubMed ID: 7706817 [TBL] [Abstract][Full Text] [Related]
58. Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling. Srivastava S; Sherman C; Meek C; Leff R; Gumbo T Antimicrob Agents Chemother; 2011 Nov; 55(11):5085-9. PubMed ID: 21896907 [TBL] [Abstract][Full Text] [Related]
59. [Testing Mycobacterium tuberculosis for drug sensitivity using different methods]. Skriagina EM; Zalutskaia OM; Roth A; Mauch H; Nikolenko EN Probl Tuberk; 2001; (5):43-5. PubMed ID: 11588962 [TBL] [Abstract][Full Text] [Related]
60. Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis. Gillespie SH; Gosling RD; Uiso L; Sam NE; Kanduma EG; McHugh TD J Antimicrob Chemother; 2005 Dec; 56(6):1169-71. PubMed ID: 16223939 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]